Search results

Read the biographies of our medical technologies advisory committee members.

Home Get involved Help develop quality standards...

Biographies and registered interests for members of the Technology Appraisal Committee A

Details and meeting dates of the antimicrobials evaluation panel

Details of the chair and core members of the public health advisory committee.

How voluntary and community sector (VCS) organisations can help NICE develop guidance

Home Get involved Help develop quality standards...

Membership details, terms of reference and future meeting dates for our quality standards advisory committee.

Help us improve NICE: take part in research to help us develop better products and services.

Home Get involved...

Join NICE's people and communities network

Making a positive impact: NICE people and communities network case studies

Embed NICE content in your digital products and services with our syndication API.

Using our content internationally. Includes information on fees and licensing agreements for both AI and non AI requests.

Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.

Learn more about what NICE content is available for reuse by checking our information asset register.

Learn about situations where you cannot use NICE content.

Find out how and where you can reuse NICE's content. Includes use of our content in the UK, use of our content internationally, use of our content for AI purposes, our content assurance process, and our information asset register.

RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.

How we collect and use your personal information, and your rights under data protection legislation.

Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.

Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.

Home What NICE does NICE International {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1

If you’re unsure where to start or your circumstances are unique, we encourage you to get in touch. We’ll work with you to unpick your challenges and find a solution that meets your needs.

The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

A step-by-step timeline of the process we used to develop single technology appraisals (STA).

Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.

An approximate guide to the timings for the development of a piece of HealthTech guidance.

Our Medical Technologies Evaluation Programme (MTEP) considers technologies that could offer benefits to patients and the health and social care system over current practice.

Our Medical Technologies Evaluation Programme (MTEP) evaluates new HealthTech.

We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.

Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.

NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.

Home What NICE does Our guidance About technology appraisal guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":

Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

NICE priority methodological research areas.

Check our list of appointed suppliers to find out which knowledge resources and services they can offer.

Home Implementing NICE guidance Cost saving, resource planning and audit {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElemen

Smoking cessation positively impacts all 5 clinical areas identified by Core20PLUS5 adults.

Oral health is one of the key clinical areas of health inequalities identified in NHS England’s Core20PLUS5 framework for children and young people.

Mental health is one of the key clinical areas of health inequalities identified in NHS England’s Core20PLUS5 framework for children and young people.

Core20PLUS5 principles for children and young people target health inequalities by focusing on deprived and vulnerable groups, addressing key clinical priorities and supporting equitable, integrated, and evidence-based care.

Ensure annual physical health checks for people with severe mental illness to at least nationally set targets.

A clear focus on Chronic Obstructive Pulmonary Disease (COPD) driving up uptake of Covid, Flu and Pneumonia vaccines to reduce infective exacerbations and emergency hospital admissions due to those exacerbations.

Epilepsy is one of the key clinical areas of health inequalities identified in NHS England’s Core20PLUS5 framework for children and young people.

Access to a range of journals, databases and other evidence-based resources for health and social care staff in England.

Home Library and knowledge services Buy books, journals and databases {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":

NHS OpenAthens eligibility covers a wide range of those working in health and care, including all staff employed by NHS Trusts. Resources are for users in England only.

A guide to the steps to follow when buying sole supplied titles from Lot 1 of our purchasing framework.